The study was terminated early due to low detection of ctDNA after treatment among patients with stage 1 to 3 breast cancer SAN ANTONIO – The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients positive for … Continue reading ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence